HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Metipranolol

Subscribe to New Research on Metipranolol

A beta-adrenergic antagonist effective for both beta-1 and beta-2 receptors. It is used as an antiarrhythmic, antihypertensive, and antiglaucoma agent.

Also Known As:

1-(4-Acetoxy-2,3,5-Trimethylphenoxy)-3-Isopropylamino-2-Propanol; Disorat; Methypranol; Trimepranol; Phenol, 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-2,3,6-trimethyl-, 1-acetate

Networked: 106 relevant articles (4 outcomes, 10 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Wood, John P M: 2 articles (07/2006 - 10/2004)
2.	Osborne, Neville N: 2 articles (07/2006 - 10/2004)
3.	Sin, Martin: 1 article (03/2015)
4.	Rehak, Jiri: 1 article (03/2015)
5.	Kandrnal, Vit: 1 article (03/2015)
6.	Jirkova, Barbora: 1 article (03/2015)
7.	Chrapek, Oldrich: 1 article (03/2015)
8.	Hommer, A: 1 article (02/2013)
9.	Díaz-Llopis, M: 1 article (03/2005)
10.	Cano Parra, J: 1 article (03/2005)

Related Diseases

1.	Open-Angle Glaucoma (Glaucoma, Open Angle) 01/01/1992 - "Two hundred and forty seven patients with open angle glaucoma who were receiving the three different strengths of metipranolol (0.1%, 0.3%, and 0.6%) in our Department and the 7 patients who participated in the metipranolol rechallenge trial were included in this study. " 01/01/1987 - "A double blind randomised study was made to compare the efficiency in decreasing intra ocular pressure of Metipranolol 0.1% or 0.3% versus placebo in three groups of 15 patients with chronic open angle glaucoma with or without visual field defects. " 12/15/1994 - "Two patients, aged 71 and 81 years, were given topical metipranolol 0.3% therapy for primary open-angle glaucoma. " 01/01/1987 - "[Metipranolol 0.1%: effect of a single dose on the nycthemeral pressure curve in an eye with chronic primary open-angle glaucoma]." 01/01/1996 - "Metipranolol is cost effective in treating primary open-angle glaucoma; however, it has been associated with more ocular burning, stinging, and granulomatous anterior uveitis than other agents. "
2.	Angina Pectoris 01/01/1983 - "Trimepranol was effective in 81% and Obsidan in 83% of patients with angina pectoris of effort. " 01/01/1983 - "In a double blind trial the authors studied the effect of beta-adrenoblocking agent Trimepranol (Spofa, Czechoslovakia), in 35 patients with ischaemic heart disease (IHD) associated with angina pectoris, and in another 42 patients they compared the effect of Trimepranol and Obsidan (GDR). "
3.	Anterior Uveitis 06/01/1999 - "Bilateral anterior uveitis associated with 0.3% minims metipranolol." 06/01/1997 - "On reinstituting metipranolol 0.3%, the patient once again developed a unilateral, nongranulomatous, anterior uveitis in the challenged eye. " 06/01/1997 - "To describe the findings in a patient with a nongranulomatous anterior uveitis, presumed to be induced by metipranolol. " 06/01/1997 - "Metipranolol-associated nongranulomatous anterior uveitis." 03/01/1997 - "Bilateral anterior uveitis associated with a brand of metipranolol."
4.	Ocular Hypertension (Glaucoma, Suspect) 09/15/1991 - "In randomized, double-masked fashion, 24 volunteers with ocular hypertension received 0.3% or 0.6% metipranolol, a noncardioselective beta blocker; or placebo twice daily to both eyes for six weeks. " 02/01/1983 - "Prophylactic Metipranolol 0,6% can substantially reduce the incidence of severe early postoperative ocular hypertension." 11/01/1988 - "Metipranolol is a non-selective beta-adrenoceptor blocking agent used for the topical treatment of elevated intraocular pressure in patients with chronic open angle glaucoma or ocular hypertension. " 01/01/1986 - "The results of this continuing multicenter study revealed a good efficacy and tolerance of Metipranolol used in patients with ocular hypertension and chronic open-angle glaucoma. " 09/15/1991 - "A clinical trial of metipranolol, a noncardioselective beta-adrenergic antagonist, in ocular hypertension."
5.	Bradycardia 02/01/1992 - "Dilthiazem must be administered with metipranolol carefully with regard to possible development of severe bradycardia and its suitable dose should be established by titration." 01/01/1983 - "Trimepranol treatment was associated with a higher incidence of side-effects such as bradycardia, arterial pressure decrease and bronchial spasm than Obsidan treatment." 04/01/1997 - "However, this rate of administration was followed by a constant reduction of HR. Thus, on a dose basis the metipranolol-pilocarpine combination appeared to be more effective in reducing IOP and less effective in inducing bradycardia than the timolol-pilocarpine association." 01/01/1989 - "Six cases of systemic reactions to topical treatment with beta-blocking eyedrops are reported, bradycardia and faintness due to an overdosage of ophthalmic timolol; decompensated heart failure one month after the prescription of carteolol eyedrops: bronchospasm after two weeks of treatment with metipranolol eyedrops; crippling Raynaud's phenomenon of otherwise unknown origin, which had begun with timolol eyedrops, continued with carteolol eyedrops and regressed after discontinuation of ophthalmic beta-blockers; aggravation of an anaphylactoid shock in a patient treated with ophthalmic timolol, and myocardial infarction possibly due to the abrupt withdrawal of timolol eyedrops. "

Related Drugs and Biologics

1.	Pilocarpine (Ocusert)
2.	Timolol (Blocadren)
3.	Propranolol (Inderal)
4.	Ophthalmic Solutions (Eye Drops)
5.	Carteolol (Carteolol Hydrochloride)
6.	Adrenergic Antagonists (Antiadrenergic Agents)
7.	Betaxolol (Kerlon)
8.	Retinaldehyde (Retinal)
9.	Metipranolol
10.	Levobunolol (AKBeta)

Related Therapies and Procedures

1.	Premedication
2.	Nephrectomy
3.	Ligation
4.	Renal Dialysis (Hemodialysis)
5.	Oral Administration